

(19) World Intellectual Property Organization  
International Bureau(43) International Publication Date  
15 September 2005 (15.09.2005)

PCT

(10) International Publication Number  
WO 2005/084653 A3

(51) International Patent Classification<sup>7</sup>: C07H 19/16, A61K 31/7076, A61P 9/00, 29/00

(21) International Application Number: PCT/GB2005/000800

(22) International Filing Date: 4 March 2005 (04.03.2005)

(25) Filing Language: English

(26) Publication Language: English

(30) Priority Data:

0405009.2	5 March 2004 (05.03.2004)	GB
0405012.6	5 March 2004 (05.03.2004)	GB
PCT/GB2004/000902		
0412262.8	5 March 2004 (05.03.2004)	GB
0412261.0	2 June 2004 (02.06.2004)	GB
0413627.1	2 June 2004 (02.06.2004)	GB
0413627.1	18 June 2004 (18.06.2004)	GB
0419718.2	6 September 2004 (06.09.2004)	GB
0420063.0	9 September 2004 (09.09.2004)	GB
0420615.7	16 September 2004 (16.09.2004)	GB

(71) Applicant (for all designated States except US): CAMBRIDGE BIOTECHNOLOGY LIMITED [GB/GB]; PO Box 230, Cambridge CB2 1XJ (GB).

(72) Inventors; and

(75) Inventors/Applicants (for US only): PRITCHARD, Martyn [GB/GB]; 9 Bury Close, St. Ives, Huntingdon, Cambs PE27 6WB (GB). OUZMAN, Jacqueline [GB/GB]; 19 Jolley Way, Cambridge CB4 2QZ (GB). SAVORY, Edward [GB/GB]; 12 Cherry Hinton Road, Teversham, Cambs, CB1 5AA (GB). BROWN, Giles [GB/GB]; 9 Brothers Place, Cambridge CB1 8BN (GB).


(74) Agent: THORNTON, Neil; Reddie & Grose, 16 Theobalds Road, London WC1X 8PL (GB).

(81) Designated States (unless otherwise indicated, for every kind of national protection available): AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SM, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW.

(84) Designated States (unless otherwise indicated, for every kind of regional protection available): ARIPO (BW, GH,

*[Continued on next page]*

(54) Title: ADENOSINE RECEPTOR AGONISTS



WO 2005/084653 A3

(57) Abstract: Use of compounds of general formula (A) as medicaments is described, in particular for the treatment of pain or inflammation; wherein: (I) when X = OH, R<sub>2</sub> = NH<sub>2</sub>, R<sub>5</sub> = CH<sub>2</sub>OH, R<sub>6</sub> = H, R<sub>1</sub> is C<sub>5</sub>-C<sub>6</sub> alkoxy, OCH<sub>2</sub>Cyclopropyl, O-(2,2,3,3-tetrafluoro-cycloButyl), phenoxy, substituted phenoxy, OCH<sub>2</sub>CH<sub>2</sub>OH, or OCH<sub>2</sub>CHF<sub>2</sub>, (5-indanyl)oxy, C<sub>1</sub>, C<sub>2</sub>, C<sub>5</sub>, or C<sub>6</sub> alkylamino, (R) or (S)-sec-Butylamino, C<sub>5</sub> or C<sub>6</sub> cycloalkylamino, exo-norbornane amino, (N-methyl, N-isoamylamino), phenylamino, phenylamino with either rnethoxy or fluoro substituents, a C<sub>2</sub> sulfone group, a C<sub>2</sub> alkyl group, a cyano group, a CONH<sub>2</sub> group, or 3,5-dimethylphenyl; or when X = H, R<sub>2</sub> = NH<sub>2</sub>, R<sub>5</sub> = CH<sub>2</sub>OH, R<sub>6</sub> = H, R<sub>1</sub> is n-hexyloxy; or (II) when X = OH, R<sub>1</sub> = H, R<sub>5</sub> = CH<sub>2</sub>OH, R<sub>6</sub> = H, R<sub>2</sub> is NMe<sub>2</sub>, N-(2-isopentenyl), piperazinyl, (N-Me, N-benzyl), (N-Me, N-CH<sub>2</sub>Ph(3-Br)), (N-Me, N-CH<sub>2</sub>Ph(3-CF<sub>3</sub>)), or (N-Me, N-(2-rnethoxyethyl)), or OCH<sub>2</sub>Cyclopentyl; or (III) when X = OH, R<sub>5</sub> = CONHR<sub>3</sub>, R<sub>6</sub> = H; R<sub>1</sub> is H, R<sub>3</sub> is an isopropyl group, and R<sub>2</sub> is either NH<sub>2</sub> or a methylamino group (NHMe) or an isoamyl group (CH<sub>2</sub>CH<sub>2</sub>CHMe<sub>2</sub>); or R<sub>1</sub> is H, R<sub>3</sub> is H, and R<sub>2</sub> is NH<sub>2</sub>; or R<sub>1</sub> is OMe, R<sub>3</sub> is Ph, and R<sub>2</sub> is NH<sub>2</sub>; or R<sub>1</sub> is NHCH<sub>2</sub>CH<sub>2</sub>CH<sub>2</sub>CH<sub>2</sub>Me, R<sub>3</sub> is CH<sub>2</sub>CH<sub>2</sub>CH<sub>2</sub>Me, and R<sub>2</sub> is NH<sub>2</sub>; or (IV) when X = OH, R<sub>1</sub> = H, R<sub>2</sub> = NH<sub>2</sub>, R<sub>5</sub> = CH<sub>2</sub>NHCOR<sub>4</sub>, R<sub>6</sub> = H, R<sub>4</sub> is n-propyl or NHCH<sub>2</sub>CH<sub>3</sub>; or (V) when X = OH, R<sub>5</sub> = CH<sub>2</sub>OH, R<sub>6</sub> = H; R<sub>1</sub> is NHCyclohexyl when R<sub>2</sub> is NMe<sub>2</sub>; or R<sub>1</sub> is OMe when R<sub>2</sub> is NHBenzyl; or (VI) when X = OH, R<sub>2</sub> = NH<sub>2</sub>, R<sub>5</sub> = CH<sub>2</sub>OH, R<sub>6</sub> = Me, R<sub>1</sub> is NHCyclohexyl or NHCyclopentyl.



GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM), European (AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LT, LU, MC, NL, PL, PT, RO, SE, SI, SK, TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG).

— before the expiration of the time limit for amending the claims and to be republished in the event of receipt of amendments

**(88) Date of publication of the international search report:**  
18 May 2006

**Published:**  
— with international search report

*For two-letter codes and other abbreviations, refer to the "Guidance Notes on Codes and Abbreviations" appearing at the beginning of each regular issue of the PCT Gazette.*